1254765-89-3

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 302348-51-2 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol 
• 73183-34-3 bis(pinacol)diborane 
• 873-75-6 4-bromobenzenemethanol 
• 128376-64-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 

Downstream Products

• 1254765-82-6 2-methyl-4-oxo-4H-pyran-3-yl 4-(4,4,5-trimethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonate 
• 1620211-54-2 C₃₆H₃₈BNO₆S 

Relevant academic research and scientific papers

Smart Responsive Quercetin-Conjugated Glycol Chitosan Prodrug Micelles for Treatment of Inflammatory Bowel Diseases

The incidence and progression of inflammatory bowel disease are closely related to oxidative stress caused by excessive production of reactive oxygen species (ROS). To develop an efficacious and safe nanotherapy against inflammatory bowel diseases (IBD),

Intracellular delivery of therapeutic proteins through N-Terminal site-specific modification

A versatile strategy for the intracellular delivery of functional proteins/antibodies was developed using N-Terminal site-specific modification. Adopting orthogonal dual-labeling strategies, a cell-permeable RNase A prodrug was designed complementing N-Te

Versatile Histochemical Approach to Detection of Hydrogen Peroxide in Cells and Tissues Based on Puromycin Staining

Hydrogen peroxide (H2O2) is a central reactive oxygen species (ROS) that contributes to diseases from obesity to cancer to neurodegeneration but is also emerging as an important signaling molecule. We now report a versatile histochemical approach for detection of H2O2 that can be employed across a broad range of cell and tissue specimens in both healthy and disease states. We have developed a first-generation H2O2-responsive analogue named Peroxymycin-1, which is based on the classic cell-staining molecule puromycin and enables covalent staining of biological samples and retains its signal after fixation. H2O2-mediated boronate cleavage uncages the puromycin aminonucleoside, which leaves a permanent and dose-dependent mark on treated biological specimens that can be detected with high sensitivity and precision through a standard immunofluorescence assay. Peroxymycin-1 is selective and sensitive enough to image both exogenous and endogenous changes in cellular H2O2 levels and can be exploited to profile resting H2O2 levels across a panel of cell lines to distinguish metastatic, invasive cancer cells from less invasive cancer and nontumorigenic counterparts, based on correlations with ROS status. Moreover, we establish that Peroxymycin-1 is an effective histochemical probe for in vivo H2O2 analysis, as shown through identification of aberrant elevations in H2O2 levels in liver tissues in a murine model of nonalcoholic fatty liver disease, thus demonstrating the potential of this approach for studying disease states and progression associated with H2O2. This work provides design principles that should enable development of a broader range of histochemical probes for biological use that operate via activity-based sensing.

Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer

In order to improve the antitumor potency of the natural product evodiamine, novel boron-containing evodiamine derivatives were designed by incorporating boronic acid and boronate as trigger units. Boronate derivative 13a could be triggered by reactive oxygen species (ROS) in the HCT116 colon cancer cell line and showed excellent antitumor activity in vitro and in vivo. It induced apoptosis in HCT116 cancer cells in a dose-dependent manner and cell growth arrest at the G2 phase.

Photoactivatable Organic Semiconducting Pro-nanoenzymes

Therapeutic enzymes hold great promise for cancer therapy; however, in vivo remote control of enzymatic activity to improve their therapeutic specificity remains challenging. This study reports the development of an organic semiconducting pro-nanoenzyme (OSPE) with a photoactivatable feature for metastasis-inhibited cancer therapy. Upon near-infrared (NIR) light irradiation, this pro-nanoenzyme not only generates cytotoxic singlet oxygen (1O2) for photodynamic therapy (PDT), but also triggers a spontaneous cascade reaction to induce the degradation of ribonucleic acid (RNA) specifically in tumor microenvironment. More importantly, OSPE-mediated RNA degradation is found to downregulate the expression of metastasis-related proteins, contributing to the inhibition of metastasis after treatment. Such a photoactivated and cancer-specific synergistic therapeutic action of OSPE enables complete inhibition of tumor growth and lung metastasis in mouse xenograft model, which is not possible for the counterpart PDT nanoagent. Thus, our study proposes a phototherapeutic-proenzyme approach toward complete-remission cancer therapy.

ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer

Background: Reactive oxygen species (ROS)-responsive drug delivery systems (DDSs) are potential tools to minimize the side effects and substantially enhance the therapeutic efficacy of chemotherapy. However, it is challenging to achieve spatially and temporally controllable and accurate drug release in tumor sites based on ROS-responsive DDSs. To solve this problem, we designed a nanosystem combined photodynamic therapy (PDT) and ROS-responsive chemotherapy. Methods: Indocyanine green (ICG), an ROS trigger and photosensitizer, and pB-DOX, a ROS-responsive prodrug of doxorubicin (DOX), were coencapsulated in polyethylene glycol modified liposomes (Lipo/pB-DOX/ICG) to construct a combination therapy nanosystem. The safety of nanosystem was assessed on normal HEK-293 cells, and the cellular uptake, intracellular ROS production capacity, target cell toxicity, and combined treatment effect were estimated on human breast cancer cells MDA-MB-231. In vivo biodistribution, biosafety assessment, and combination therapy effects were investigated based on MDA-MB-231 subcutaneous tumor model. Results: Compared with DOX·HCl, Lipo/pB-DOX/ICG showed higher safety on normal cells. The toxicity of target cells of Lipo/pB-DOX/ICG was much higher than that of DOX·HCl, Lipo/pB-DOX, and Lipo/ICG. After endocytosis by MDA-MB-231 cells, Lipo/pB-DOX/ICG produced a large amount of ROS for PDT by laser irradiation, and pB-DOX was converted to DOX by ROS for chemotherapy. The cell inhibition rate of combination therapy reached up to 93.5 %. After the tail vein injection (DOX equivalent of 3.0?mg/kg, ICG of 3.5?mg/kg) in mice bearing MDA-MB-231 tumors, Lipo/pB-DOX/ICG continuously accumulated at the tumor site and reached the peak at 24?h post injection. Under irradiation at this time point, the tumors in Lipo/pB-DOX/ICG group almost disappeared with 94.9 % tumor growth inhibition, while those in the control groups were only partially inhibited. Negligible cardiotoxicity and no treatment-induced side effects were observed. Conclusions: Lipo/pB-DOX/ICG is a novel tool for on-demand drug release at tumor site and also a promising candidate for controllable and accurate combinatorial tumor therapy.[Figure not available: see fulltext.]

Fluorescent probe as well as preparation method and application thereof

The invention provides a fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of hydrogen peroxide detection. The fluorescent probe provided by the invention has a structure as shown in a formula I. Molecules of the fluorescent probe provided by the invention contain a phenylboronic acid ester structure capable of acting with hydrogen peroxide, so that the fluorescent probe has interference resistance to other substances such as active oxygen, active nitrogen and active sulfur, and has high selectivity to hydrogen peroxide; the phenylboronic acid ester in the fluorescent probe is disconnected after reacting with hydrogen peroxide and is oxidized into hydroxyl, wherein the fluorescence intensity of the fluorescent probe is improved by about 30 times compared with that before reacting with hydrogen peroxide, and the color and fluorescence change sensitivity is high, so that high-selectivity and high-sensitivity recognition and detection of hydrogen peroxide in water or cells are realized; moreover, the fluorescence probe molecule provided by the invention has good cell penetrating permeability and low toxicity, and can realize fluorescence detection of hydrogen peroxide in cells; in conclusion, the fluorescence probe has a good application prospect in detection of hydrogen peroxide in water or cells.

FLUOROGENIC BETA-LACTAMASE SUBSTRATE AND ASSOCIATED DETECTION METHOD

This invention relates to probes for the detection of β-lactamase-type enzymatic activity. In particular, the invention relates to novel fluorogenic substrates for detecting the presence of a catalytically active β-lactamase and a detection method using such substrates.

Doxorubicin prodrug with borate structure, and synthesis method thereof

The invention discloses a doxorubicin prodrug with a borate structure, and a synthesis method thereof. The synthesis method comprises the following steps: dissolving p-hydroxymethyl phenylboronic acid pinacol ester and 4-dimethylaminopyridine in anhydrous tetrahydrofuran according to a certain ratio, adding the solution into p-nitro phenyl chloroformate for reaction, and separating and purifying to obtain a white benzyl carbonate crystal; preparing an intermediate a and an intermediate b; and adding the intermediate b and the intermediate a into N, N-dimethylformamide according to a certain ratio, and reacting to obtain a target product. The doxorubicin prodrug is scientific and reasonable in structural design, the structure of the doxorubicin prodrug contains a borate group which is easily oxidized by active oxygen, and the doxorubicin prodrug breaks in the presence of the active oxygen to release doxorubicin. And functional molecules such as histidine and cholesterol in the structure also endow the hydrogel with the functions of lysosome escape, matching of a drug loading system and the like.

Antibiotic modified anticancer compounds for the treatment of non-genetic anti-cancer and anticancer pharmaceutical composition comprising the same

The present invention relates to an antibiotic modified anti-cancer compound for gene non-toxic anticancer therapy and an anticancer pharmaceutical composition comprising the same. A method for treating mitochondria target using a compound according to th